开云app官网登录入口网页版-官方正版

#ruxolitinib#

13篇内容 | 1087人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1493214, encodeId=4ed91493214bc, content=<a href='/topic/show?id=ea4815e48e2' target=_blank style='color:#2F92EE;'>#ruxolitinib#</a>, objectTitle=Blood：BH3图谱分析发现ruxolitinib可与ventoclax联合治疗前体T淋巴细胞白血病, objectType=article, longId=207368, objectId=dbc020e368b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbc020e368b8, replyNumber=0, likeNumber=83, createdTime=2021-02-22, rootId=0, userName=zhanfl, userId=7b038999222, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbc020e368b8, moduleTitle=Blood：BH3图谱分析发现ruxolitinib可与ventoclax联合治疗前体T淋巴细胞白血病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dbc020e368b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493213, encodeId=25d214932136e, content=<a href='/topic/show?id=ea4815e48e2' target=_blank style='color:#2F92EE;'>#ruxolitinib#</a>, objectTitle=NEJM：Ruxolitinib可显著降低异基因干细胞移植后急性移植物抗宿主病风险, objectType=article, longId=192867, objectId=c31919286ec8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c31919286ec8, replyNumber=0, likeNumber=64, createdTime=2020-04-25, rootId=0, userName=zhanfl, userId=7b038999222, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c31919286ec8, moduleTitle=NEJM：Ruxolitinib可显著降低异基因干细胞移植后急性移植物抗宿主病风险, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c31919286ec8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493212, encodeId=d3e514932126c, content=<a href='/topic/show?id=ea4815e48e2' target=_blank style='color:#2F92EE;'>#ruxolitinib#</a>, objectTitle=NEJM：Jakavi（ruxolitinib）治疗急性移植物抗宿主病，优于现有更佳疗法, objectType=article, longId=192864, objectId=1334192864b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1334192864b9, replyNumber=0, likeNumber=76, createdTime=2020-04-25, rootId=0, userName=zhanfl, userId=7b038999222, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1334192864b9, moduleTitle=NEJM：Jakavi（ruxolitinib）治疗急性移植物抗宿主病，优于现有更佳疗法, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1334192864b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493211, encodeId=0f541493211ce, content=<a href='/topic/show?id=ea4815e48e2' target=_blank style='color:#2F92EE;'>#ruxolitinib#</a>, objectTitle=JAK抑制剂ruxolitinib治疗重度COVID-19患者：正在进行评估, objectType=article, longId=191368, objectId=f47919136872, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f47919136872, replyNumber=0, likeNumber=70, createdTime=2020-04-05, rootId=0, userName=zhanfl, userId=7b038999222, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f47919136872, moduleTitle=JAK抑制剂ruxolitinib治疗重度COVID-19患者：正在进行评估, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f47919136872)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493210, encodeId=f92614932102c, content=<a href='/topic/show?id=ea4815e48e2' target=_blank style='color:#2F92EE;'>#ruxolitinib#</a>, objectTitle=Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功, objectType=article, longId=188485, objectId=ddfc1884854b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddfc1884854b, replyNumber=0, likeNumber=74, createdTime=2020-02-22, rootId=0, userName=zhanfl, userId=7b038999222, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddfc1884854b, moduleTitle=Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ddfc1884854b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493209, encodeId=09251493209ef, content=<a href='/topic/show?id=ea4815e48e2' target=_blank style='color:#2F92EE;'>#ruxolitinib#</a>, objectTitle=NEJM：JAK抑制剂ruxolitinib治疗遗传性USP18缺乏症, objectType=article, longId=188465, objectId=e9c4188465bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9c4188465bc, replyNumber=0, likeNumber=69, createdTime=2020-02-21, rootId=0, userName=zhanfl, userId=7b038999222, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9c4188465bc, moduleTitle=NEJM：JAK抑制剂ruxolitinib治疗遗传性USP18缺乏症, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e9c4188465bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493208, encodeId=5dd21493208ee, content=<a href='/topic/show?id=ea4815e48e2' target=_blank style='color:#2F92EE;'>#ruxolitinib#</a>, objectTitle=特应性皮炎的治疗进展：ruxolitinib乳膏制剂效果良好, objectType=article, longId=186960, objectId=0abc1869602b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0abc1869602b, replyNumber=0, likeNumber=73, createdTime=2020-01-31, rootId=0, userName=zhanfl, userId=7b038999222, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0abc1869602b, moduleTitle=特应性皮炎的治疗进展：ruxolitinib乳膏制剂效果良好, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0abc1869602b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493207, encodeId=e9ef149320e87, content=<a href='/topic/show?id=ea4815e48e2' target=_blank style='color:#2F92EE;'>#ruxolitinib#</a>, objectTitle=Incyte宣布开展Ruxolitinib的III期临床试验, objectType=article, longId=156672, objectId=aeee1566e228, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeee1566e228, replyNumber=0, likeNumber=74, createdTime=2018-12-27, rootId=0, userName=zhanfl, userId=7b038999222, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeee1566e228, moduleTitle=Incyte宣布开展Ruxolitinib的III期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aeee1566e228)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493206, encodeId=6abe14932067f, content=<a href='/topic/show?id=ea4815e48e2' target=_blank style='color:#2F92EE;'>#ruxolitinib#</a>, objectTitle=Lancet Haematol：Janus激酶-2抑制剂fedratinib在先前用ruxolitinib治疗的骨髓纤维化患者中的治疗效果, objectType=article, longId=101497, objectId=250110149ec1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=250110149ec1, replyNumber=0, likeNumber=63, createdTime=2017-06-12, rootId=0, userName=zhanfl, userId=7b038999222, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=250110149ec1, moduleTitle=Lancet Haematol：Janus激酶-2抑制剂fedratinib在先前用ruxolitinib治疗的骨髓纤维化患者中的治疗效果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=250110149ec1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493205, encodeId=fa701493205c7, content=<a href='/topic/show?id=ea4815e48e2' target=_blank style='color:#2F92EE;'>#ruxolitinib#</a>, objectTitle=J Clin Invest：脱发落发？试试ruxolitinib效果不错, objectType=article, longId=78668, objectId=ba40e86683c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba40e86683c, replyNumber=0, likeNumber=62, createdTime=2016-09-29, rootId=0, userName=zhanfl, userId=7b038999222, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba40e86683c, moduleTitle=J Clin Invest：脱发落发？试试ruxolitinib效果不错, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ba40e86683c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493204, encodeId=bc1f14932041e, content=<a href='/topic/show?id=ea4815e48e2' target=_blank style='color:#2F92EE;'>#ruxolitinib#</a>, objectTitle=NEJM：Ruxolitinib用于真性红细胞增多症的治疗, objectType=article, longId=47323, objectId=b8f04e3231c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8f04e3231c, replyNumber=0, likeNumber=65, createdTime=2015-02-22, rootId=0, userName=zhanfl, userId=7b038999222, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8f04e3231c, moduleTitle=NEJM：Ruxolitinib用于真性红细胞增多症的治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b8f04e3231c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493203, encodeId=6c7414932034c, content=<a href='/topic/show?id=ea4815e48e2' target=_blank style='color:#2F92EE;'>#ruxolitinib#</a>, objectTitle=FDA批准ruxolitinib用于骨髓纤维化治疗面临质疑, objectType=article, longId=4282, objectId=7c2a42829a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c2a42829a, replyNumber=0, likeNumber=59, createdTime=2012-03-12, rootId=0, userName=zhanfl, userId=7b038999222, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c2a42829a, moduleTitle=FDA批准ruxolitinib用于骨髓纤维化治疗面临质疑, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7c2a42829a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493202, encodeId=bffe1493202e4, content=<a href='/topic/show?id=ea4815e48e2' target=_blank style='color:#2F92EE;'>#ruxolitinib#</a>, objectTitle=FDA批准治疗骨髓纤维化药ruxolitinib上市, objectType=article, longId=3356, objectId=44913356f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44913356f5, replyNumber=0, likeNumber=60, createdTime=2011-11-30, rootId=0, userName=zhanfl, userId=7b038999222, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44913356f5, moduleTitle=FDA批准治疗骨髓纤维化药ruxolitinib上市, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=44913356f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

ruxolitinib

2020-05-29

zhanfl (审核中...)

前往app查看评论内容

#ruxolitinib#

Blood：BH3图谱分析发现ruxolitinib可与ventoclax联合治疗前体T淋巴细胞白血病

2021-02-22

zhanfl (审核中...)

前往app查看评论内容

#ruxolitinib#

NEJM：Ruxolitinib可显著降低异基因干细胞移植后急性移植物抗宿主病风险

2020-04-25

zhanfl (审核中...)

前往app查看评论内容

#ruxolitinib#

NEJM：Jakavi（ruxolitinib）治疗急性移植物抗宿主病，优于现有更佳疗法

2020-04-25

zhanfl (审核中...)

前往app查看评论内容

#ruxolitinib#

JAK抑制剂ruxolitinib治疗重度COVID-19患者：正在进行评估

2020-04-05

zhanfl (审核中...)

前往app查看评论内容

#ruxolitinib#

Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功

2020-02-22

zhanfl (审核中...)

前往app查看评论内容

#ruxolitinib#

NEJM：JAK抑制剂ruxolitinib治疗遗传性USP18缺乏症

2020-02-21

zhanfl (审核中...)

前往app查看评论内容

#ruxolitinib#

特应性皮炎的治疗进展：ruxolitinib乳膏制剂效果良好

2020-01-31

zhanfl (审核中...)

前往app查看评论内容

#ruxolitinib#

Incyte宣布开展Ruxolitinib的III期临床试验

2018-12-27

zhanfl (审核中...)

前往app查看评论内容

#ruxolitinib#

Lancet Haematol：Janus激酶-2抑制剂fedratinib在先前用ruxolitinib治疗的骨髓纤维化患者中的治疗效果

2017-06-12

zhanfl (审核中...)

前往app查看评论内容

#ruxolitinib#

J Clin Invest：脱发落发？试试ruxolitinib效果不错

2016-09-29

zhanfl (审核中...)

前往app查看评论内容

#ruxolitinib#

NEJM：Ruxolitinib用于真性红细胞增多症的治疗

2015-02-22

zhanfl (审核中...)

前往app查看评论内容

#ruxolitinib#

FDA批准ruxolitinib用于骨髓纤维化治疗面临质疑

2012-03-12

zhanfl (审核中...)

前往app查看评论内容

#ruxolitinib#

FDA批准治疗骨髓纤维化药ruxolitinib上市

2011-11-30

科室
- - 订阅+
  - 更多科室
工具
服务